HUE060655T2 - Új alkilálási reagens - Google Patents

Új alkilálási reagens

Info

Publication number
HUE060655T2
HUE060655T2 HUE19184082A HUE19184082A HUE060655T2 HU E060655 T2 HUE060655 T2 HU E060655T2 HU E19184082 A HUE19184082 A HU E19184082A HU E19184082 A HUE19184082 A HU E19184082A HU E060655 T2 HUE060655 T2 HU E060655T2
Authority
HU
Hungary
Prior art keywords
alkylating agents
new alkylating
new
agents
alkylating
Prior art date
Application number
HUE19184082A
Other languages
English (en)
Hungarian (hu)
Inventor
Italo Beria
Michele Caruso
Vittoria Lupi
Paolo Orsini
Matteo Salsa
Achille Panzeri
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of HUE060655T2 publication Critical patent/HUE060655T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HUE19184082A 2012-04-05 2013-03-28 Új alkilálási reagens HUE060655T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12163459 2012-04-05
EP12176162 2012-07-12

Publications (1)

Publication Number Publication Date
HUE060655T2 true HUE060655T2 (hu) 2023-04-28

Family

ID=48092927

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE19184082A HUE060655T2 (hu) 2012-04-05 2013-03-28 Új alkilálási reagens

Country Status (10)

Country Link
US (2) US9527863B2 (https=)
EP (2) EP2836494B1 (https=)
JP (2) JP6314128B2 (https=)
CN (2) CN104220442B (https=)
DK (1) DK2836494T3 (https=)
ES (2) ES2929759T3 (https=)
HR (1) HRP20221356T1 (https=)
HU (1) HUE060655T2 (https=)
RU (1) RU2632206C2 (https=)
WO (1) WO2013149948A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6251236B2 (ja) * 2012-04-05 2017-12-20 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 癌を治療するための官能性チエノ−インドール誘導体
WO2013149948A1 (en) 2012-04-05 2013-10-10 Nerviano Medical Sciences S.R.L. New alkylating agents
JP6487422B2 (ja) * 2013-09-25 2019-03-20 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 新しい抗腫瘍剤としてのチエノ[2,3−e]インドール誘導体
US10870706B2 (en) 2015-03-20 2020-12-22 Pfizer Inc. Bifunctional cytotoxic agents containing the CTI pharmacophore
WO2017012924A1 (en) * 2015-07-21 2017-01-26 Nerviano Medical Sciences S.R.L. Asymmetric process for the preparation of thieno-indoles derivatives
JP6486316B2 (ja) 2015-11-03 2019-03-20 財團法人工業技術研究院Industrial Technology Research Institute 抗体−薬物複合体(adc)およびそれを形成するための方法
CN109641911B (zh) * 2016-08-19 2023-02-21 百时美施贵宝公司 seco-环丙吡咯并吲哚化合物和其抗体-药物缀合物以及制备和使用方法
EP4221705A1 (en) * 2020-09-09 2023-08-09 Clinuvel (UK) Ltd. Pyrrolidine compounds to treat xeroderma pigmentosum

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0065393B1 (en) * 1981-05-12 1984-12-27 Imperial Chemical Industries Plc Pyrrole derivatives
CA1238907A (en) * 1984-02-21 1988-07-05 Robert C. Kelly 1,2,8,8a-tetrahydrocyclopropa¬c|pyrrolo(3,2-e)- indol-4(5h)-ones and related compounds
US5659022A (en) * 1996-01-05 1997-08-19 Epoch Pharmaceuticals, Inc. Oligonucleotide-cyclopropapyrroloindole conjugates as sequence specific hybridization and crosslinking agents for nucleic acids
JP3045706B1 (ja) 1998-09-14 2000-05-29 科学技術振興事業団 Dnaの特定塩基配列をアルキル化する化合物及びその合成法
GB2344818A (en) 1998-12-16 2000-06-21 Pharmacia & Upjohn Spa Anti-tumour thieno-indole derivatives
GB0015447D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl derivates and alkylating agents
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US7129261B2 (en) * 2001-05-31 2006-10-31 Medarex, Inc. Cytotoxic agents
CA2459308A1 (en) * 2001-09-07 2003-03-20 Dale L. Boger Cbi analogues of cc-1065 and the duocarmycins
WO2003026577A2 (en) * 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
US6756397B2 (en) * 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
JP2006507322A (ja) 2002-11-14 2006-03-02 シンタルガ・ビーブイ 多重自己脱離放出スペーサーとして構築されたプロドラッグ
US20070037739A1 (en) * 2003-02-03 2007-02-15 Medlogics Device Corporation Compounds useful in coating stents to prevent and treat stenosis and restenosis
TW200526204A (en) * 2004-02-03 2005-08-16 Pharmacia Italia Spa 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
US7282590B2 (en) 2004-02-12 2007-10-16 The Research Foundation Of State University Of New York Drug conjugates
US20050265925A1 (en) 2004-04-21 2005-12-01 Samuel Zalipsky Releasable linkage and compositions containing same
JP4806680B2 (ja) * 2004-05-19 2011-11-02 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
RU2402548C2 (ru) * 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
JP5149620B2 (ja) 2004-07-23 2013-02-20 エンドサイト,インコーポレイテッド 2価リンカーおよびその結合体
EP1994000B1 (en) * 2006-02-02 2017-08-23 Syntarga B.V. Water-soluble cc-1065 analogs and their conjugates
EP2120932B1 (en) * 2006-12-20 2014-07-09 Nerviano Medical Sciences S.r.l. Indazole derivatives as kinase inhibitors for the treatment of cancer
CN102159248B (zh) 2008-07-15 2013-09-11 健泰科生物技术公司 蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途
WO2013149948A1 (en) 2012-04-05 2013-10-10 Nerviano Medical Sciences S.R.L. New alkylating agents
JP6251236B2 (ja) * 2012-04-05 2017-12-20 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 癌を治療するための官能性チエノ−インドール誘導体

Also Published As

Publication number Publication date
US10071074B2 (en) 2018-09-11
CN104220442B (zh) 2016-11-23
EP3587426B1 (en) 2022-08-10
CN107011358A (zh) 2017-08-04
JP6314128B2 (ja) 2018-04-18
ES2929759T3 (es) 2022-12-01
US20170071907A1 (en) 2017-03-16
ES2755719T3 (es) 2020-04-23
WO2013149948A1 (en) 2013-10-10
HRP20221356T1 (hr) 2022-12-23
EP2836494B1 (en) 2019-08-21
CN104220442A (zh) 2014-12-17
JP2018070599A (ja) 2018-05-10
HK1203957A1 (en) 2015-11-06
DK2836494T3 (da) 2019-11-11
RU2632206C2 (ru) 2017-10-03
JP2015514101A (ja) 2015-05-18
US20150051154A1 (en) 2015-02-19
EP3587426A1 (en) 2020-01-01
EP2836494A1 (en) 2015-02-18
CN107011358B (zh) 2020-05-05
US9527863B2 (en) 2016-12-27
RU2014143994A (ru) 2016-05-27

Similar Documents

Publication Publication Date Title
EP2934531A4 (en) COMBINATION
EP2911673A4 (en) COMBINATION
HUE060655T2 (hu) Új alkilálási reagens
SG11201503816PA (en) Alkylating process
GB2500883B (en) Improved saw-horse
GB201219483D0 (en) Helico-airboat
EP2925728A4 (en) COMBINATION
GB201220591D0 (en) Improved soap
ZA201305187B (en) Improved brattice
EP2908816A4 (en) ASSOCIATION
EP2908815A4 (en) COMBINATION
GB201215711D0 (en) Higher
GB201216178D0 (en) Combination
GB201219610D0 (en) Moviebook
GB201218969D0 (en) Ezesip
GB201218804D0 (en) PI-switch
GB201218705D0 (en) Corcost-5457987546
GB201218424D0 (en) Drydam
GB201218139D0 (en) Drydam
GB201216197D0 (en) Clearwheels
GB201215229D0 (en) Tangley
GB201215003D0 (en) Immortaliser
GB201215083D0 (en) Paw-2-bowl
GB201214161D0 (en) Rubblett
GB201213137D0 (en) Corcost-456879854